Work

461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.637

Authors: J.L. Blum, G. Rocque, Y. Ji, T. Pluard, J. Migas, S. Lakhanpal, E. Jepsen, E. Gauthier, Y. Wang, M.Z. Montelongo, J. Cappelleri, C. Chen, M.S. Karuturi, D. Tripathy

Institutions: University of Alabama at Birmingham, HealthPartners, Saint Luke's Hospital, Mid Illinois Hematology and Oncology Associates, St. Vincent's Birmingham, Novant Health, Pfizer (United States), ICON PLC (Ireland), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Jazz Pharmaceuticals, BeiGene, Puma Biotechnology, Flatiron Health, Genentech, ImmunoMedics

OpenAlex ID: W4387825856

FWCI: 0.642

Cites:

Cited by: 4

Related to: 10